Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

James R. Patrinely; Rebecca Johnson; Aleigha Lawless; Prachi Bhave; Amelia Sawyers; Maya Dimitrova; Hui‐Ling Yeoh; Marisa Palmeri; Fei Ye; Run Fan; Elizabeth J. Davis; Suthee Rapisuwon; Georgina V. Long; Andrew Haydon; Iman Osman; Janice M. Mehnert; Matteo S. Carlino; Ryan J. Sullivan; Alexander M. Menzies; Douglas B. Johnson

doi:10.1001/jamaoncol.2021.0051

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this multicenter cohort study, chronic irAEs associated with anti-PD-1 therapy appear to be more common than previously recognized and frequently persisted even with prolonged follow-up, although most were low grade. The risks of chronic irAEs should be integrated into treatment decision-making.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Patrinely et al. (2021) studied this question.

synapsesocial.com/papers/69d91684d8690e49a78358b5 https://doi.org/10.1001/jamaoncol.2021.0051

View Full Paper

Ask AI

Bookmark

Share

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Ask about this paper

Abstract

Discussion

Cite This Study

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading